Table 2.
Patient outcomes by World Bank income group
Overall (n=1319) | Low-income or lower-middle-income country (n=296) | Upper-middle-income country (n=709) | High-income country (n=314) | ||
---|---|---|---|---|---|
Disease severity | |||||
Asymptomatic | 456/1301 (35·0%) | 87/288 (30·2%) | 233/702 (33·2%) | 136/311 (43·7%) | |
Mild or moderate | 586/1301 (45·0%) | 81/288 (28·1%) | 353/702 (50·3%) | 152/311 (48·9%) | |
Severe or critical | 259/1301 (19·9%) | 120/288 (41·7%) | 116/702 (16·5%) | 23/311 (7·4%) | |
Treatment modification* | |||||
Treatment modified | 609/1092 (55·8%) | 163/240 (67·9%) | 299/622 (48·1%) | 147/230 (63·9%) | |
Chemotherapy reduced | 80/609 (13·1%) | 34/163 (20·9%) | 41/299 (13·7%) | 5/147 (3·4%) | |
Chemotherapy withheld | 487/609 (80·0%) | 125/163 (76·7%) | 234/299 (78·3%) | 128/147 (87·1%) | |
Radiotherapy delayed | 25/609 (4·1%) | 3/163 (1·8%) | 14/299 (4·7%) | 8/147 (5·4%) | |
Surgery delayed | 41/609 (6·7%) | 10/163 (6·1%) | 20/299 (6·7%) | 11/147 (7·5%) | |
Treatment on plan (includes unknown) | 483/1092 (44·2%) | 77/240 (32·1%) | 323/622 (51·9%) | 83/230 (36·1%) | |
Death | |||||
Due to COVID-19 | 50/83 (60·2%) | 20/33 (60·6%) | 26/43 (60·5%) | 4/7 (57·1%) | |
Median time to death, days | 8 (3–14) | 9 (4–13) | 7 (3–13) | 20 (11–25) | |
Due to other causes | 33/83 (39·8%) | 13/33 (39·4%) | 17/43 (39·5%) | 3/7 (42·9%) | |
Median time to death, days | 16 (8–29) | 16 (8–29) | 10 (4–21) | 26 (24–32) | |
Hospitalisation | |||||
Hospitalised, ward status | 658 (49·9%) | 61 (20·6%) | 472 (66·6%) | 125 (39·8%) | |
Hospitalised, higher level of care† | 231 (17·5%) | 117 (39·5%) | 95 (13·4%) | 19 (6·1%) | |
Not hospitalised | 430 (32·6%) | 118 (39·9%) | 142 (20·0%) | 170 (54·1%) |
Data are n, n/N (%), n (%), or median (IQR).
Treatment modification corresponds to a “select all that apply” question in the survey, thus sum of count numbers could exceed total number.
Higher level of care included intensive care unit, intermediate care unit, high dependency unit, and emergency room.